Jane Rhyu, Sylvia Lambrechts, Maria A Han, Matthew J Freeby
Curr Opin Endocrinol Diabetes Obes. 2022;29(1):29-33
In this review article, the authors describe HbA1c testing as a marker of glycemic control and the standard for diabetes risk assessment. They highlight that many diabetes patients have uncontrolled diabetes, increasing the risk of microvascular complications. They explain that a lack of HbA1c monitoring presents a significant barrier and that improving ease of testing could improve glycemic control.
Point-of-care testing (POCT) for HbA1c provides results immediately and is available and used frequently in endocrine clinics. However, the authors describe how testing is not standard in primary care, where 90% of type 2 diabetes patients are treated. Barriers include access and costs of POCT machines and standardisation of testing in the primary care setting. The authors cite that POCT in primary care may lead to HbA1c reduction, is potentially cost-effective and may also strengthen the patient-physician relationship.
The authors conclude that POCT in primary care, if widely available and integrated into workflow, has the potential to positively impact diabetes care by allowing earlier therapeutic intervention.
The full publication can be accessed here.
&cópia de; 2022 Abbott. Todos os direitos reservados. Todas as marcas comerciais mencionadas são marcas comerciais do grupo de empresas Abbott ou de seus respectivos proprietários.
Kunihiro Matsushita, Josef Coresh, Yingying Sang, John Chalmers, Caroline Fox, Eliseo Guallar, Tazeen Jafar, Simerjot K Jassal, Gijs W D Landman, Paul Muntner, Paul Roderick, Toshimi Sairenchi, Ben Schöttker, Anoop Shankar, Michael Shlipak, Marcello Tonelli, Jonathan Townend, Arjan van Zuilen, Kazumasa Yamagishi, Kentaro Yamashita, Ron Gansevoort, Mark Sarnak, David G Warnock, Mark Woodward, Johan Ärnlöv, CKD Prognosis Consortium
Estimated glomerular filtration rate and albumin-to-creatinine ratio testing for cardiovascular risk assessmentenAcesse agora
Johan Sundström, Johan Bodegard, Andreas Bollmann, Marc G Vervloet, Patrick B Mark, Avraham Karasik, Tiago Taveira-Gomes, Manuel Botana, Kåre I Birkeland, Marcus Thuresson, Levy Jäger, Manish M Sood, Gijs VanPottelbergh, Navdeep Tangri; on behalf of the CaReMe CKD Investigators
Prevalence, outcomes and cost of chronic kidney diseaseenAcesse agora